# Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

Source: https://onco.cc/trials/nct06435260/  
OnCo record `nct06435260` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab in pancreatic cancer, run by Hebei Medical University Fourth Hospital, now recruiting.

## Summary

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer is a phase 2, interventional study registered as NCT06435260 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 30 participants, started 2024-08-01 and due to reach its primary completion in 2025-06-01. Interventions recorded: Camrelizumab+chemotherapy; hypofractionated radiotherapy. Conditions listed: Pancreatic Cancer. Primary outcome: a.R0-resection rate. Pancreatic eligibility wording from the registry: "Tumor was located in the pancreas;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06435260
- Phase: 2
- Setting: To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer
- Sponsor: Hebei Medical University Fourth Hospital
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06435260: https://clinicaltrials.gov/study/NCT06435260

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06435260.json